IQI0 Stock Overview
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Incannex Healthcare Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.43 |
52 Week High | US$1.78 |
52 Week Low | US$1.43 |
Beta | 2.09 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -86.32% |
Recent News & Updates
Recent updates
Shareholder Returns
IQI0 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | -2.2% | -1.4% |
1Y | n/a | -27.0% | 2.2% |
Return vs Industry: Insufficient data to determine how IQI0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IQI0 performed against the German Market.
Price Volatility
IQI0 volatility | |
---|---|
IQI0 Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IQI0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IQI0's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | n/a | Joel Latham | www.incannex.com |
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.
Incannex Healthcare Inc. Fundamentals Summary
IQI0 fundamental statistics | |
---|---|
Market cap | €59.85m |
Earnings (TTM) | -€12.23m |
Revenue (TTM) | €620.84k |
Over9,999x
P/S Ratio-624.0x
P/E RatioIs IQI0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IQI0 income statement (TTM) | |
---|---|
Revenue | AU$1.01m |
Cost of Revenue | AU$0 |
Gross Profit | AU$1.01m |
Other Expenses | AU$20.99m |
Earnings | -AU$19.98m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.013 |
Gross Margin | 100.00% |
Net Profit Margin | -1,970.61% |
Debt/Equity Ratio | 0% |
How did IQI0 perform over the long term?
See historical performance and comparison